Illumina gets a $40M commitment to back genomic startups; Biota bags Anaconda and lead antiviral in buyout;

@FierceBiotech: After painful odyssey, Newron wins European OK for Parkinson's add-on. News | Follow @FierceBiotech

@JohnCFierce: Top story of the week: Exclusive: Pfizer is once again cutting back R&D staff in reorganization. Report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online and subscribe on iTunes. | Follow @DamianFierce

> San Francisco-based Illumina ($ILMN) reports that it has gained a $40 million commitment from Viking Global Investors to seed promising genomic startups that come out of its incubator. Release

> Atlanta-based Biota ($BOTA) has acquired Paris-based Anaconda Pharma and its lead antiviral for $8 million in cash, 3.5 million shares and up to $30 million in milestones. Anaconda Pharma's lead candidate is AP611074, an antiviral in development for condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis. Release

> Amarin ($AMRN) is getting $15 million upfront and up to $154 million in milestones from Eddingpharm in exchange for development and commercialization rights to Vascepa in China. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: In a medical first, three patients receive prosthetic hands in place of disabled ones. Article | Follow @FierceMedDev

@VarunSaxena2: Roche, BioMed X to jointly run diagnostics incubator in Germany. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Cyberonics and Sorin to form U.K.-based company valued at $2.7B, aiming to boost hospital offerings. More from Bloomberg | Follow @EmilyWFierce

> Indian diagnostics company Thyrocare aims for $100M IPO. News

> FDA warns manufacturer of failing to report corrections to its device disinfection system. Report

Pharma News

@FiercePharma: Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Sidelined after tampering incident, GSK's alli is back on sale. Report | Follow @CarlyHFierce

> SC's top court backs Risperdal verdict against J&J, but cuts penalty to $136M. Story

> Sanofi's fight for Toujeo market share won't be easy, analysts say. Article

Vaccines News

> NewLink nets $20M Ebola milestone from Merck. Item

> Valeant touts PhII Provenge data following Dendreon buy. More

> Takeda places vaccines unit in Singapore to push for global growth. Article

> Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results. Story

> Pfizer trumpets positive Trumenba data ahead of ACIP vote. Report

Pharma Manufacturing News

> Impax reports significant jump in revenues as it gets plant problems behind it. Report

> Unused Forest Labs facility snapped up by Aprecia Pharmaceuticals. News

> New Jersey compounder indicted over unsanitary manufacturing. Story

> Bharat, Serum Institute ramp up production of their swine flu vaccines. Item

> Federal judge cuts off Maine's Internet drug supply chain. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.